{"id":15436,"date":"2025-04-10T11:24:30","date_gmt":"2025-04-10T11:24:30","guid":{"rendered":"https:\/\/exam.pscnotes.com\/current-affairs\/?p=15436"},"modified":"2025-04-10T11:25:36","modified_gmt":"2025-04-10T11:25:36","slug":"apl-leukemia","status":"publish","type":"post","link":"https:\/\/exam.pscnotes.com\/current-affairs\/apl-leukemia\/","title":{"rendered":"APL Leukemia"},"content":{"rendered":"<ul>\n<li>\n<p><strong>APL is a Rare, Aggressive Leukemia:<\/strong> Acute Promyelocytic Leukemia (APL) is a rare subtype of Acute Myeloid Leukemia (AML), accounting for 10-15% of AML cases. It&#8217;s characterized by abnormal white blood cell formation due to a genetic mutation (PML-RARA gene fusion).<\/p>\n<\/li>\n<li>\n<p><strong>Dangerous Bleeding Risk:<\/strong> APL can cause sudden and severe internal bleeding, potentially fatal if untreated.<\/p>\n<\/li>\n<li>\n<p><strong>High Curability with Early Treatment:<\/strong> APL is highly curable if diagnosed and treated early with treatments like all-trans retinoic acid (ATRA) and arsenic trioxide.<\/p>\n<\/li>\n<li>\n<p><strong>New Rapid Diagnostic Test (RAPID-CRISPR):<\/strong> A new CRISPR-based test, RAPID-CRISPR, has been developed for faster and more accessible APL diagnosis.<\/p>\n<\/li>\n<li>\n<p><strong>Current Tests are Slow and Complex:<\/strong> Existing diagnostic tests are time-consuming, require specialized equipment, and trained personnel, limiting accessibility.<\/p>\n<\/li>\n<li>\n<p><strong>RAPID-CRISPR Advantages:<\/strong><\/p>\n<ul>\n<li>Provides results in under 3 hours.<\/li>\n<li>More affordable than existing tests.<\/li>\n<li>Doesn&#8217;t require complex lab equipment.<\/li>\n<li>Nearly 100% sensitivity and specificity.<\/li>\n<\/ul>\n<\/li>\n<li>\n<p><strong>How RAPID-CRISPR Works:<\/strong> Detects the PML-RARA gene mutation in a blood sample <div class=\"youtube-subscribe-container\">\r\n        <a href=\"https:\/\/www.youtube.com\/channel\/UCNHT8lW-JmLC68rjBfZhdkg?sub_confirmation=1\" target=\"_blank\" class=\"youtube-subscribe-button\">\r\n            <span class=\"youtube-icon\">\r\n                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 576 512\">\r\n                    <path d=\"M549.7 124.1c-6.3-23.7-24.8-42.3-48.3-48.6C458.8 64 288 64 288 64S117.2 64 74.6 75.5c-23.5 6.3-42 24.9-48.3 48.6-11.4 42.9-11.4 132.3-11.4 132.3s0 89.4 11.4 132.3c6.3 23.7 24.8 41.5 48.3 47.8C117.2 448 288 448 288 448s170.8 0 213.4-11.5c23.5-6.3 42-24.2 48.3-47.8 11.4-42.9 <div class=\"telegram-channel-container\">\r\n        <a href=\"https:\/\/t.me\/pscnotes2025\" target=\"_blank\" class=\"telegram-channel-button\">\r\n            <span class=\"telegram-icon\">\r\n                <svg xmlns=\"http:\/\/www.w3.org\/2000\/svg\" viewBox=\"0 0 496 512\">\r\n                    <path fill=\"white\" d=\"M248,8C111,8,0,119,0,256s111,248,248,248s248-111,248-248S385,8,248,8z M362,177L320,367c-3,14-10,18-20,14l-56-41l-27,26 c-3,3-5,5-10,5l4-63L323,196c5-5-1-7-8-3l-98,62l-42-13c-9-3-10-9,2-14l162-63C351,160,365,164,362,177z\"\/>\r\n                <\/svg>\r\n            <\/span>\r\n            Join Our Telegram Channel\r\n        <\/a>\r\n    <\/div> 11.4-132.3 11.4-132.3s0-89.4-11.4-132.3zm-317.5 213.5V175.2l142.7 81.2-142.7 81.2z\"\/>\r\n                <\/svg>\r\n            <\/span>\r\n            Subscribe on YouTube\r\n        <\/a>\r\n    <\/div> and triggers a signal detected by a simple strip, similar to a home pregnancy test.<\/p>\n<\/li>\n<li>\n<p><strong>Potential for Widespread Use:<\/strong> RAPID-CRISPR can bridge the gap in diagnosis in resource-limited settings, enabling timely treatment. The goal is to make it a standard tool in hospitals worldwide and, potentially, for at-home testing.<\/p>\n<\/li>\n<\/ul>\n","protected":false},"excerpt":{"rendered":"<p>APL is a Rare, Aggressive Leukemia: Acute Promyelocytic Leukemia (APL) is a rare subtype of Acute Myeloid Leukemia (AML), accounting for 10-15% of AML cases. It&#8217;s characterized by abnormal white blood cell formation due to a genetic mutation (PML-RARA gene fusion). Dangerous Bleeding Risk: APL can cause sudden and severe internal bleeding, potentially fatal if &#8230; <a title=\"APL Leukemia\" class=\"read-more\" href=\"https:\/\/exam.pscnotes.com\/current-affairs\/apl-leukemia\/\">Read more <span class=\"screen-reader-text\">APL Leukemia<\/span><\/a><\/p>\n","protected":false},"author":1,"featured_media":15449,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[595],"tags":[1270],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v22.2 (Yoast SEO v23.3) - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>APL Leukemia - Current Affairs Exam<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/exam.pscnotes.com\/current-affairs\/apl-leukemia\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"APL Leukemia\" \/>\n<meta property=\"og:description\" content=\"APL is a Rare, Aggressive Leukemia: Acute Promyelocytic Leukemia (APL) is a rare subtype of Acute Myeloid Leukemia (AML), accounting for 10-15% of AML cases. It&#8217;s characterized by abnormal white blood cell formation due to a genetic mutation (PML-RARA gene fusion). Dangerous Bleeding Risk: APL can cause sudden and severe internal bleeding, potentially fatal if ... Read more APL Leukemia\" \/>\n<meta property=\"og:url\" content=\"https:\/\/exam.pscnotes.com\/current-affairs\/apl-leukemia\/\" \/>\n<meta property=\"og:site_name\" content=\"Current Affairs Exam\" \/>\n<meta property=\"article:published_time\" content=\"2025-04-10T11:24:30+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2025-04-10T11:25:36+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/exam.pscnotes.com\/current-affairs\/wp-content\/uploads\/sites\/307\/2025\/04\/15436_1744284333.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"940\" \/>\n\t<meta property=\"og:image:height\" content=\"530\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"rawan239\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"rawan239\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"APL Leukemia - Current Affairs Exam","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/exam.pscnotes.com\/current-affairs\/apl-leukemia\/","og_locale":"en_US","og_type":"article","og_title":"APL Leukemia","og_description":"APL is a Rare, Aggressive Leukemia: Acute Promyelocytic Leukemia (APL) is a rare subtype of Acute Myeloid Leukemia (AML), accounting for 10-15% of AML cases. It&#8217;s characterized by abnormal white blood cell formation due to a genetic mutation (PML-RARA gene fusion). Dangerous Bleeding Risk: APL can cause sudden and severe internal bleeding, potentially fatal if ... Read more APL Leukemia","og_url":"https:\/\/exam.pscnotes.com\/current-affairs\/apl-leukemia\/","og_site_name":"Current Affairs Exam","article_published_time":"2025-04-10T11:24:30+00:00","article_modified_time":"2025-04-10T11:25:36+00:00","og_image":[{"width":940,"height":530,"url":"https:\/\/exam.pscnotes.com\/current-affairs\/wp-content\/uploads\/sites\/307\/2025\/04\/15436_1744284333.jpg","type":"image\/jpeg"}],"author":"rawan239","twitter_card":"summary_large_image","twitter_misc":{"Written by":"rawan239","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"WebPage","@id":"https:\/\/exam.pscnotes.com\/current-affairs\/apl-leukemia\/","url":"https:\/\/exam.pscnotes.com\/current-affairs\/apl-leukemia\/","name":"APL Leukemia - Current Affairs Exam","isPartOf":{"@id":"https:\/\/exam.pscnotes.com\/current-affairs\/#website"},"primaryImageOfPage":{"@id":"https:\/\/exam.pscnotes.com\/current-affairs\/apl-leukemia\/#primaryimage"},"image":{"@id":"https:\/\/exam.pscnotes.com\/current-affairs\/apl-leukemia\/#primaryimage"},"thumbnailUrl":"https:\/\/exam.pscnotes.com\/current-affairs\/wp-content\/uploads\/sites\/307\/2025\/04\/15436_1744284333.jpg","datePublished":"2025-04-10T11:24:30+00:00","dateModified":"2025-04-10T11:25:36+00:00","author":{"@id":"https:\/\/exam.pscnotes.com\/current-affairs\/#\/schema\/person\/5807dafeb27d2ec82344d6cbd6c3d209"},"breadcrumb":{"@id":"https:\/\/exam.pscnotes.com\/current-affairs\/apl-leukemia\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/exam.pscnotes.com\/current-affairs\/apl-leukemia\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/exam.pscnotes.com\/current-affairs\/apl-leukemia\/#primaryimage","url":"https:\/\/exam.pscnotes.com\/current-affairs\/wp-content\/uploads\/sites\/307\/2025\/04\/15436_1744284333.jpg","contentUrl":"https:\/\/exam.pscnotes.com\/current-affairs\/wp-content\/uploads\/sites\/307\/2025\/04\/15436_1744284333.jpg","width":940,"height":530},{"@type":"BreadcrumbList","@id":"https:\/\/exam.pscnotes.com\/current-affairs\/apl-leukemia\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/exam.pscnotes.com\/current-affairs\/"},{"@type":"ListItem","position":2,"name":"APL Leukemia"}]},{"@type":"WebSite","@id":"https:\/\/exam.pscnotes.com\/current-affairs\/#website","url":"https:\/\/exam.pscnotes.com\/current-affairs\/","name":"Current Affairs Exam","description":"","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/exam.pscnotes.com\/current-affairs\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/exam.pscnotes.com\/current-affairs\/#\/schema\/person\/5807dafeb27d2ec82344d6cbd6c3d209","name":"rawan239","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/exam.pscnotes.com\/current-affairs\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/d97f17072bfa490596c8f78363955d55?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/d97f17072bfa490596c8f78363955d55?s=96&d=mm&r=g","caption":"rawan239"},"sameAs":["https:\/\/exam.pscnotes.com"],"url":"https:\/\/exam.pscnotes.com\/current-affairs\/author\/rawan239\/"}]}},"amp_enabled":true,"_links":{"self":[{"href":"https:\/\/exam.pscnotes.com\/current-affairs\/wp-json\/wp\/v2\/posts\/15436"}],"collection":[{"href":"https:\/\/exam.pscnotes.com\/current-affairs\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/exam.pscnotes.com\/current-affairs\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/exam.pscnotes.com\/current-affairs\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/exam.pscnotes.com\/current-affairs\/wp-json\/wp\/v2\/comments?post=15436"}],"version-history":[{"count":0,"href":"https:\/\/exam.pscnotes.com\/current-affairs\/wp-json\/wp\/v2\/posts\/15436\/revisions"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/exam.pscnotes.com\/current-affairs\/wp-json\/wp\/v2\/media\/15449"}],"wp:attachment":[{"href":"https:\/\/exam.pscnotes.com\/current-affairs\/wp-json\/wp\/v2\/media?parent=15436"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/exam.pscnotes.com\/current-affairs\/wp-json\/wp\/v2\/categories?post=15436"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/exam.pscnotes.com\/current-affairs\/wp-json\/wp\/v2\/tags?post=15436"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}